Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Citi
Accenture
Boehringer Ingelheim
Julphar
Merck
Argus Health
Chubb
Farmers Insurance

Generated: November 17, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FAMOTIDINE

« Back to Dashboard

Clinical Trials for Famotidine

Trial ID Title Status Sponsor Phase Summary
NCT00141960 Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease Completed Astellas Pharma Inc Phase 2/Phase 3 Gastroesophageal reflux disease (GERD) considered to be associated with mucosal damages in the esophagus and heartburn, which may sometimes interfere with daily activities due likely to reflux of acid gastric contents. While most of the patients given the diagnosis of GERD do not exhibit endoscopically obvious impairment in esophageal mucous membrane, they have subjective symptoms of non-erosive GERD including heartburn. But no drug has been launched in Japan, which targets non-erosive GERD. This study will examine the efficacy and safety of famotidine in subjects with non-erosive GERD.
NCT00153673 Effect of Selective COX-2 Inhibition on Ulcer Healing Suspended Chinese University of Hong Kong Phase 3 The purpose of this study is to compare the effect of Famotidine plus a COX-2 inhibitor (celecoxib) with Famotidine plus dologesics in ulcer healing in arthritis patients.
NCT00229424 Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine - Completed UCB Pharma Phase 3 The purpose of the study is to verify superiority of the lafutidine group over the placebo group and non-inferiority to the famotidine group in terms of endoscopic healing rate of the patients with mild reflux oesophagitis. Furthermore, the followings are compared: The improvement effect in heartburn and other subjective symptoms, and dosing frequency of MALFA ® suspension (neutralizer) as well as incidence of adverse events among the lafutidine 20 mg/day treatment group, the famotidine 40 mg/day treatment group and the placebo treatment group in patients with mild reflux oesophagitis.
NCT00229424 Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine - Completed Taiho Pharmaceutical Co., Ltd. Phase 3 The purpose of the study is to verify superiority of the lafutidine group over the placebo group and non-inferiority to the famotidine group in terms of endoscopic healing rate of the patients with mild reflux oesophagitis. Furthermore, the followings are compared: The improvement effect in heartburn and other subjective symptoms, and dosing frequency of MALFA ® suspension (neutralizer) as well as incidence of adverse events among the lafutidine 20 mg/day treatment group, the famotidine 40 mg/day treatment group and the placebo treatment group in patients with mild reflux oesophagitis.
NCT00365339 Drug Interaction Study With Famotidine, Atazanavir, and Atazanavir/Ritonavir/Tenofovir Completed Bristol-Myers Squibb Phase 1 The purpose of this clinical research study is to assess the pharmacokinetics of atazanavir, identifying one or more dosing regimens of atazanavir/ritonavir/tenofovir when dosed with famotidine results in atazanavir exposures similar to those when atazanavir/ritonavir/tenofovir 300/100/300 mg is dosed without famotidine in healthy subjects.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Famotidine

Condition Name

Condition Name for Famotidine
Intervention Trials
Healthy 5
Peptic Ulcer 4
HIV Infections 3
Cancer 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Famotidine
Intervention Trials
Ulcer 9
Peptic Ulcer 6
Carcinoma 4
Gastroesophageal Reflux 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Famotidine

Trials by Country

Trials by Country for Famotidine
Location Trials
United States 47
China 16
Taiwan 9
Korea, Republic of 8
Canada 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Famotidine
Location Trials
Texas 11
California 6
Florida 4
Pennsylvania 4
Massachusetts 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Famotidine

Clinical Trial Phase

Clinical Trial Phase for Famotidine
Clinical Trial Phase Trials
Phase 4 16
Phase 3 10
Phase 2/Phase 3 2
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Famotidine
Clinical Trial Phase Trials
Completed 36
Recruiting 12
Terminated 4
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Famotidine

Sponsor Name

Sponsor Name for Famotidine
Sponsor Trials
M.D. Anderson Cancer Center 5
Horizon Pharma Ireland, Ltd., Dublin Ireland 5
Bristol-Myers Squibb 4
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Famotidine
Sponsor Trials
Other 48
Industry 33
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Boehringer Ingelheim
Daiichi Sankyo
AstraZeneca
Healthtrust
Deloitte
US Department of Justice
Accenture
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.